Mesenchymal stem cell therapy in patients with Crohn’s disease — 5 year follow-up
-
Published:2022-12-01
Issue:5-6
Volume:76
Page:618-622
-
ISSN:2255-890X
-
Container-title:Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
-
language:en
-
Short-container-title:
Author:
Knyazev Oleg V.123, Kagramanova Anna V.12, Parfenov Asfold I.1
Affiliation:
1. Moscow Clinical Scientific Center named after A. S. Loginov , 86 Shosse Entuziastov, 111123 , Moscow , Russia 2. Research Institute of Healthcare Organization and Medical Management , 9 Sharikopodshipnikovskaya Str., 115088 Moscow , Russia 3. National Medical Research Сenter of Coloproctology named after A. N. Ryzhykh , , Moscow , Russia
Abstract
Abstract
We investigated the efficacy of combination therapy using bone marrow-derived mesenchymal stromal cells (MSC) and Infliximab (IFX) to achieve “deep remission” in patients with luminal Crohn disease (CD). Our study included 72 patients (age 19–62 years) (Ме = 29) with luminal CD. Patients in the 1st group (n = 21) received standard 5-aminosalicylic acid (5-ASA) and glucocorticosteroid therapy in combination with MSC. Patients in the 2nd group (n = 32) were prescribed anti-cytokine therapy IFX. Patients in the 3rd group (n = 19) received MSC and IFX. Clinical and immunobiological (C-reactive protein-CRP and faecal calprotectin-FCP) showed a more significant decrease of local and systemic inflammation activity in the 3rd group of patients. During a 5-year follow-up we observed longer duration of remission in patients who received MSC and IFX compared to the 1st (р = 0,04) and 2nd groups of patients (р = 0.038). Combination therapy of bone marrow-derived MSC and IFL provides “deep remission” in patients with luminal CD and has higher prognostic value for duration of CD remission period.
Publisher
Walter de Gruyter GmbH
Reference17 articles.
1. Baert, F. J., D’Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., Rutgeerts, P. J. (1999). Tumor necrosis factor alpha antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn’s ileocolitis. Gastroenterology, 116 (1), 22–28.10.1016/S0016-5085(99)70224-6 2. Best, W. R., Becktel, J. M., Singleton, J. W., Kern Jr., F. (1976). Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology, 70 (3), 439–444.10.1016/S0016-5085(76)80163-1 3. Colombel, J., Rutgeerts, P., Sandborn, W. J. (2010). Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn’s disease: Results from EXTEND. J. Crohn’s Colitis, 4, S11. Abstract OP31. 4. Colombel, J., Rutgeerts, P., Sandborn, W. J. (2010). Deep remission predicts long-term outcomes for adalimumab-treated patients with Crohn’s disease: Data from EXTEND. Gut, 59 (Suppl. 3), A80. Abstract OP371. 5. Das, M., Sundell, I. B., Koka, P. S. (2013). Adult mesenchymal stem cells and their potency in the cellbased therapy. J. Stem Cells, 8 (1), 1–16.
|
|